8-K: Shuttle Pharmaceuticals Announces Restatement of Prior Financial Statements Due to Accounting Errors

Shuttle Pharmaceuticals has determined that its financial statements for 2022, 2023, and the first quarter of 2024 require restatement due to accounting errors related to stock compensation, convertible notes, and preferred stock.

Summary

• Shuttle Pharmaceuticals has identified accounting errors that necessitate the restatement of its financial statements for the year ended December 31, 2022, the year ended December 31, 2023, and the quarter ended March 31, 2024.
• The errors primarily involve stock compensation, convertible notes, warrants, and Series A Convertible Preferred Stock.
• The estimated impact on the 2022 income statement is a $0.0 million change in the reported loss, but an increase in the net loss attributable to common stockholders of $0.6 million, from $3.1 million to $3.7 million.
• The estimated impact on the 2022 balance sheet is an increase to additional paid-in capital of $7.7 million and an offsetting increase to accumulated deficit of approximately $7.7 million.
• The balance sheets as of December 31, 2023, and March 31, 2024, also require adjustments to increase additional paid-in capital by approximately $7.7 million and increase accumulated deficit by approximately $7.7 million.
• The company will file amended reports on Form 10-K/A for 2023 and Form 10-Q/A for the first quarter of 2024 as soon as reasonably practical.
• The accounting errors did not affect the company's cash balances or operating cash flows.
• A material weakness in internal controls related to complex accounting for debt and equity transactions was previously disclosed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financial statements and the identification of material weaknesses in internal controls. While the cash flow was not impacted, the need for restatement and the errors in accounting are concerning.

Positives

• The accounting errors did not impact the company's cash balances or operating cash flows.

Negatives

• The company's financial statements for 2022, 2023, and Q1 2024 are unreliable and require restatement.
• There were material weaknesses in internal controls related to complex accounting for debt and equity transactions.
• The net loss attributable to common stockholders for 2022 will increase by $0.6 million.

Risks

• The restatement of financial statements could negatively impact investor confidence.
• The material weakness in internal controls could lead to future accounting errors.
• The ongoing review of the accounting errors may result in further changes to the restatement amounts.

Future Outlook

The company anticipates filing amended reports on Form 10-K/A for the year ended December 31, 2023, and Form 10-Q/A for the quarter ended March 31, 2024, as soon as reasonably practical.

Management Comments

• The company and the audit committee of our board of directors, in consultation with our current auditor, Forvis Mazars LLP, have concluded that our audited financial statements for the year ended December 31, 2022, our audited financial statements for the year ended December 31, 2023 and the quarterly periods included in the Company's Annual Report for the year ended December 31, 2023, and the quarterly report for the period ended March 31, 2024 require restatement and are not reliable.
• The accounting errors had no impact on our cash balances or operating cash flows.

Industry Context

This announcement highlights the importance of robust internal controls and accurate financial reporting, particularly for companies with complex debt and equity transactions. The restatement follows a cease-and-desist order against the company's former auditor, which is a significant event that can impact investor confidence.

Comparison to Industry Standards

• Restatements of financial statements are not uncommon, but they are generally viewed negatively by investors as they indicate potential issues with a company's accounting practices and internal controls.
• Companies in the pharmaceutical and biotech sectors, like Shuttle Pharmaceuticals, often have complex financial structures due to research and development activities, which can lead to accounting challenges.
• The fact that the restatement is due to errors in stock compensation, convertible notes, and preferred stock accounting is not unusual, as these areas can be complex and require careful analysis.
• The impact on the net loss is relatively small, but the impact on the balance sheet is more significant, indicating that the errors were primarily related to the classification of equity and debt.

Stakeholder Impact

• Shareholders may experience a decrease in confidence due to the restatement of financial statements.
• Employees may be concerned about the company's financial stability and internal controls.
• Creditors may reassess the company's creditworthiness due to the accounting errors.

Next Steps

• The company will file amended reports on Form 10-K/A for the year ended December 31, 2023.
• The company will file amended reports on Form 10-Q/A for the quarter ended March 31, 2024.
• The company will continue to evaluate the identified accounting errors in the context of its internal controls over financial reporting.

Key Dates

Keywords

restatement, financial statements, accounting errors, internal controls, stock compensation, convertible notes, preferred stock, audit, Form 10-K, Form 10-Q